This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Obagi® Medical Products Presents Study Results At American Academy Of Dermatology

Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, released the results of three new studies this weekend at the American Academy of Dermatology meeting in San Diego, CA. The studies explored the use of the Nu-Derm System with tretinoin, as prescribed by the investigators, in the treatment of melasma and hyperpigmentation in patients with Fitzpatrick skin types III – VI. Each study evaluated the efficacy and tolerability of the treatment on the skin as well as its effects on the patients’ emotional well-being.

“Nu-Derm with tretinoin has long been a go-to regimen, particularly in difficult-to-treat melasma, for many dermatologists,” Jim Hartman, Vice President Global Marketing and Business Development at Obagi, said. “Our objective in partnering with these respected experts in the field of dermatology for these studies was to provide clinical proof that Nu-Derm, in combination with varying percentages of tretinoin, based on recommendations from key opinion leaders, is a valid, effective option in many skin types, including darker skin patients, as well as in patients more sensitive to irritation. The results presented this weekend indicate that we successfully met that objective.”

The 75 patients in the three studies followed a morning regimen that included a foaming gel cleanser, toner, four percent hydroquinone product, exfoliation enhancer and a sunscreen with SPF 35. The evening regimen consisted of a foaming gel cleanser, toner and four percent hydroquinone product mixed with a tretinoin cream at various percentages. Patients reported high levels of patient satisfaction and improved quality of life metrics across the studies.

The studies postered and affiliated investigators are as follows:

Study 4581 - Treatment of Moderate or Marked Melasma in Darker Skin with a Four Percent Hydroquinone Skin Care System Plus 0.025% Tretinoin Cream:
  • Lead investigator for Study 4581 is Pearl Grimes, MD (Los Angeles, CA)

Study 5131 - Treatment of Moderate or Marked Melasma with a Four Percent Hydroquinone Skin Care System Plus 0.1 Percent Tretinoin Cream: Comparison in Asian and Caucasian Patients:
  • Lead investigator for Study 5131 is Dr. Suzanne Bruce (Suzanne Bruce & Associates, PA; Houston, TX)

Study 5139 - Treatment of Moderate or Marked Melasma in Darker Skin with a Four Percent Hydroquinone Skin Care System Plus 0.05% Tretinoin Cream:
  • Lead investigators for Study 5139 are Michael Gold, MD (Nashville, TN), Marta Rendon, MD (Boca Raton, FL), Barry DiBernardo, MD (Monclair, NJ), Suzanne Bruce (Suzanne Bruce & Associates, PA; Houston, TX) and Chere Lucas-Anthony, MD (Boca Raton, FL)

The investigators reported considerable improvements in melasma and skin discoloration, in addition to high levels of patient satisfaction across all three studies.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%
YHOO $36.59 -0.97%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs